TuisNG9 • FRA
add
NeoGenomics, Inc.
Vorige sluiting
€8,25
Dagwisseling
€8,50 - €8,50
Jaarwisseling
€4,20 - €11,30
Markkapitalisasie
1,28 mjd USD
Gemiddelde volume
3,00
P/V-verhouding
-
Dividend-opbrengs
-
Primêre beurs
NASDAQ
In die nuus
Finansieel
Inkomstestaat
Inkomste
Netto inkomste
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Inkomste | 190,17 m | 10,56% |
Bedryfskoste | 95,82 m | 3,53% |
Netto inkomste | -9,88 m | 35,52% |
Netto winsgrens | -5,20 | 41,64% |
Wins per aandeel | 0,06 | 50,00% |
EBITDA | 3,91 m | 35,35% |
Effektiewe belastingkoers | 20,35% | — |
Balansstaat
Totale bates
Totale aanspreeklikheid
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Kontant en korttermynbeleggings | 159,62 m | -58,74% |
Totale bates | 1,36 mjd | -16,98% |
Totale aanspreeklikheid | 523,27 m | -28,87% |
Totale ekwiteit | 836,56 m | — |
Uitstaande aandele | 129,81 m | — |
Prys om te bespreek | 1,27 | — |
Opbrengs op bates | -2,28% | — |
Opbrengs op kapitaal | -2,50% | — |
Kontantvloei
Netto kontantverandering
| (USD) | Des. 2025info | J/J-verandering |
|---|---|---|
Netto inkomste | -9,88 m | 35,52% |
Kontant van bedrywe | 1,34 m | -86,30% |
Kontant van beleggings | -6,30 m | -15,33% |
Kontant van finansiering | 431,00 k | -37,26% |
Netto kontantverandering | -4,50 m | -189,62% |
Beskikbare kontantvloei | 618,38 k | -80,33% |
Meer oor
NeoGenomics Laboratories, Inc., also known as NeoGenomics or Neo, is an American CLIA-certified clinical laboratory, pharma services and information services company that specializes in cancer genetics diagnostic testing. The company's testing services include cytogenetics, fluorescence in situ hybridization, flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics.
Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US, with laboratories in Florida, California, Tennessee, and Texas. Wikipedia
Gestig
2002
Hoofkwartier
Webwerf
Werknemers
2 500
